Product logins

Find logins to all Clarivate products below.


Acute Coronary Syndrome – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of ACS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence of ACS for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s ACS forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of ACS and the number of new diagnosed?
  • Of all people diagnosed with ACS, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • Of all people diagnosed with ACS, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ACS over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following ACS subpopulations:

  • Top-line epidemiology: Diagnosed ACS events
  • Diagnosed ACS 12-month prevalent cases
  • Diagnosed ACS lifetime prevalent cases
  • Diagnosed NSTEMI ACS 12-month prevalent cases
  • Diagnosed STEMI ACS 12-month prevalent cases
  • Diagnosed US ACS 12-month prevalent cases
  • Diagnosed drug-treated ACS events
  • Diagnosed events by subtype
  • Diagnosed events by comorbidity

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Heart Failure (US)
Chronic heart failure (CHF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. The CHF therapy market…
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…
Report
Pulmonary Hypertension – Current Treatment – Current Treatment: Physician Insights – Pulmonary Arterial Hypertension (US)
Pulmonary arterial hypertension (PAH) treatment in the United States is undergoing notable shifts as physicians increasingly adopt guidelinealigned early combination therapy, driving steady use of…